Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface

Similar Items

• Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
  od: White, Maya N, i dr.
  Izdano: (2021)
• Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
  od: Jiang, Tao, i dr.
  Izdano: (2020)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  od: Ricciuti, Biagio, i dr.
  Izdano: (2018)
• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  od: Imamura, Fumio, i dr.
  Izdano: (2020)
• ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
  od: Li, Yiting, i dr.
  Izdano: (2019)